PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity

Kohay, Hagay; Sarısözen, Can; Sawant, Rupa R.; Jhaveri, Aditi; Torchilin, Vladimir P.; Mishael, Yael G.

doi:10.1016/j.actbio.2017.04.008

Cited by 34 publications

(20 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many nano-sized drug delivery systems, such as natural and synthetic polymer nanoparticles, metal nanoparticles, and polymer-drug conjugates, have been investigated for delivery of anti-tumor drugs (Ekladious et al, 2018; Liu et al, 2018; Maeki et al, 2018). The nano-vehicles basing on phosphoethanolamine-polyethylene glycol polymers (PEG-PE) represent a promising nanoparticles delivery system owing to biocompatibility, prolonged circulation, and accumulation in tumors by the enhanced permeability and retention (EPR) effect (Perche et al, 2012; Kohay et al, 2017). In the past decade, many efforts have been made to prepare liver-targeting nano-carriers, which were modified by sugars, antibodies, and other ligands (Singh et al, 2016; Zhu et al, 2016; Yan et al, 2017; Wu J. et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA

et al. 2019

View full text Add to dashboard Cite

Combination therapy based on nano-sized drug delivery system has been developed as a promising strategy by combining two or more anti-tumor mechanisms. Here, we prepared liver-targeted nanoparticles (GH-DPP) composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-polyetherimide (DSPE-PEG-PEI) with Glycyrrhetinic acid-modified hyaluronic acid (GA-HA) for co-delivery of doxorubicin (DOX) and Bcl-2 siRNA. Particles size, zeta potential and morphology were determined for the drug-loaded GH-DPP nanoparticles (siRNA/DOX/GH-DPP). Cellular uptake and in vitro cytotoxicity were analyzed against HepG2 cells. In vivo bio-distribution and anti-tumor therapeutic effects of siRNA/DOX/GH-DPP were evaluated in H22-bearing mice. The results showed that siRNA/DOX/GH-DPP nanoparticles were nearly spherical and showed dose-dependent cytotoxicity against HepG2 cells. Compared to Glycyrrhetinic acid-free co-delivery system (siRNA/DOX/DPP) and GH-DPP nanoparticles for delivery of DOX or Bcl-2 siRNA alone, siRNA/DOX/GH-DPP nanoparticles could induce more cellular apoptosis, and showed higher anti-tumor effect. Herein GH-DPP nanoparticles could simultaneously deliver both chemotherapy drugs and siRNA into the tumor region, exhibiting great potential in anti-tumor therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Despite desirable preclinical research, monotherapy nanomedicines remain largely unsuccessful for producing enhanced response rates on traditional chemotherapy in clinical trials (Cheng et al, 2013 ; He et al, 2015 ). Recent efforts (Yan et al, 2016 ; Kohay et al, 2017 ) are underway to exploit nanocarriers for efficiently delivering multiple chemotherapeutic agents to boost target section convergences and control release traits (Hu et al, 2016 ). Chitosan (CS) has nontoxicity, biodegradability and good biocompatibility.…”

Section: Introductionmentioning

confidence: 99%

Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy

et al. 2018

View full text Add to dashboard Cite

Combination chemotherapy is widely exploited for suppressing drug resistance and achieving synergistic anticancer efficacy in the clinic. In this paper, the nanostructured targeting methotrexate (MTX) plus pemetrexed (PMX) chitosan nanoparticles (CNPs) were developed by modifying methoxy polye (thylene glycol) (mPEG), in which PEGylation CNPs was used as stealth nanocarriers (PCNPs) and MTX was employed as a targeting ligand and chemotherapeutic agent as well. Studies were undertaken on human lung adenocarcinoma epithelial (A549) and Lewis lung carcinoma (LLC) cell lines, revealing the anti-tumor efficacy of nanoparticle drug delivery system. The co-delivery nanoparticles (MTX-PMX-PCNPs) had well-dispersed with sustained release behavior. Cell counting kit-8 (CCK8) has been used to measure A549 cell viability and the research showed that MTX-PMX-PCNPs were much more effective than free drugs when it came to the inhibition of growth and proliferation. Cell cycle assay by flow cytometry manifested that the MTX-PMX-PCNPs exhibited stronger intracellular taken up ability than free drugs at the same concentration. In vivo anticancer effect results indicated that MTX-PMX-PCNPs exhibited a significantly prolong blood circulation, more tumoral location accumulation, and resulted in a robust synergistic anticancer efficacy in lung cancer in mice. The results clearly demonstrated that such unique synergistic anticancer efficacy of co-delivery of MTX and PMX via stealth nanocarriers, providing a prospective strategy for lung cancer treatment.

show abstract

“…However, there is still no systematic research on the in vivo anticancer activity of various Dox formulations for ovarian cancer treatment. Due to its intrinsic fluorescence and structural properties, Dox has been widely utilized for drug delivery studies as an imaging agent and anticancer drug in combination with nanodrug carriers such as inorganic nanoparticles [23][24][25], dendrimers [26][27][28], and graphene oxide [29,30], etc [31][32][33][34].…”

Section: Introductionmentioning

confidence: 99%

In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment

Lee

Kim

et al. 2020

Cancers

View full text Add to dashboard Cite

In this study, we have determined the anticancer activity of doxorubicin (Dox)-loaded DNA/gold nanoparticle (AuNP) nanocarrier (Dox-DNA-AuNP) for the treatment of ovarian cancer. The anticancer effect of Dox-DNA-AuNP was evaluated in vitro using the EZ-Cytox cell viability assay on three human ovarian cancer cell lines, SK-OV-3, HEY A8, and A2780. Dox-DNA-AuNP exhibited outstanding activity with good IC50 values of 4.8, 7.4, and 7.6 nM for SK-OV-3, HEY A8, and A2780, respectively. In vivo evaluation further demonstrated the superior anticancer effects of Dox-DNA-AuNP by inhibiting tumor growth compared to free Dox in an established SK-OV-3 xenograft mice model. Dox-DNA-AuNP showed about a 2.5 times higher tumor growth inhibition rate than free Dox. Furthermore, the immunohistochemical analysis of Ki67 antigen expression showed the lowest number of proliferative cells in the ovarian tumor tissue treated with Dox-DNA-AuNP. These results suggest Dox-DNA-AuNP might be a potential effective agent in ovarian cancer chemotherapy.

show abstract

PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity

Cited by 34 publications

References 68 publications

Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA

Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA

Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy

In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment

Contact Info

Product

Resources

About